Amgen Inc. Common Stock (AMGN)
Stock · NASDAQ · Health Care
$432.49as of 10/16/2026
Price chart
Active signals
AMGN Signal Track Record
How signals performed across all stocks →What AMGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +2.3% | 61% | September 8, 2026 |
| Bollinger Band Breakout | 28 | +3.5% | 57% | August 19, 2026 |
| Bollinger Band Breakdown | 21 | +2.4% | 62% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +3.7% | 67% | May 18, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEV…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 31,500
- Website
- www.amgen.com/
Fundamentals
- 1-day range
- $434.58$438.82
- Market cap
- $218.50B
- P/E (trailing)
- 26.35
- P/E (forward)
- 17.81
- EPS (trailing)
- $16.10
- Dividend yield
- 3.21%
- Beta
- 0.44
- Avg. volume
- 2.81M
- Ex-dividend date
- August 21, 2026
- Dividend pay date
- September 11, 2026
How Amgen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
29 analyst ratings
Amgen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AMGNAmgen Inc. Common Stock$432.49▼ 0.35%Market cap $218.50BP/E 26.35$288$447.03
- GILDGilead Sciences Inc. Common Stock$156.19▼ 0.75%Market cap $162.47BP/E —$114.02$157.29
- ARGXargenx SE American Depositary Shares$819.14▼ 3.21%Market cap $54.32BP/E 21.26$568.4$925
- RVMDRevolution Medicines Inc. Common Stock$177.96▼ 5.97%Market cap $42.05BP/E —$47.45$224.31
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AMGN Amgen Inc. Common Stock | $218.50B | 26.35 | $432.49 | ▼ 0.35% | $288$447.03 |
| GILD Gilead Sciences Inc. Common Stock | $162.47B | — | $156.19 | ▼ 0.75% | $114.02$157.29 |
| ARGX argenx SE American Depositary Shares | $54.32B | 21.26 | $819.14 | ▼ 3.21% | $568.4$925 |
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $177.96 | ▼ 5.97% | $47.45$224.31 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Veeva Systems’ (VEEV) Comeback Gets Jim Cramer TalkingYahoo · 10/10/2026
- Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth NewsYahoo · 10/9/2026
- Amgen (AMGN) Laps the Stock Market: Here's WhyYahoo · 10/9/2026
- Friday's session: top gainers and losers in the dow jones indexChartMill · 10/9/2026
- The Tax Math That Makes These High-Yield Dividend Stocks Worth Much More Annually Inside a RothYahoo · 10/9/2026
- Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impactYahoo · 10/9/2026
- Top dow jones movers in Friday's sessionChartMill · 10/9/2026
- A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That HappensYahoo · 10/9/2026
Insider Activity
Insider Actions →- Rachna Khosla · August 13, 2026 · Option Exercise1.3K @ $162.6
- Rachna Khosla · August 13, 2026 · Sale1.3K @ $416.43
- Rachna Khosla · August 11, 2026 · Sale2.0K @ $412.57
- Matthew C. Busch · August 7, 2026 · Grant730
- Michael Drake V · August 7, 2026 · Grant64
- Omar Ishrak · August 7, 2026 · Grant85
- Charles M. Holley · August 7, 2026 · Grant103
- Nancy A. Grygiel · August 6, 2026 · Option Exercise2.0K @ $177.46
- Nancy A. Grygiel · August 6, 2026 · Sale1.0K @ $402.16
- Nancy A. Grygiel · August 6, 2026 · Sale2.0K @ $402.16
- Derek Miller · August 6, 2026 · Option Exercise1.8K @ $177.46
- Derek Miller · August 6, 2026 · Option Exercise2.1K @ $162.6
- Derek Miller · August 6, 2026 · Sale1.8K @ $402.54
- Derek Miller · August 6, 2026 · Sale2.1K @ $402.54
- Nancy A. Grygiel · August 6, 2026 · Option Exercise1.0K @ $177.31
Institutional Ownership
March 31, 2026
- Total shares held
- 408.43M
- Total value held
- $140.14B
- Institutional holders
- 3107
- Unknown47.10M
- Unknown35.01M
- Unknown30.55M
- Unknown29.29M
- Unknown15.84M
- Unknown15.43M
- Unknown12.77M
- Unknown8.87M
- Unknown7.12M
- Unknown7.09M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Amgen Outperforms Market Amid Dow Jones Rotation
Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.
Amgen Outperforms Market Amid Dow Jones Rotation. Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.